Assuming the results are positive, I actually think the market's...

Assuming the results are positive, I actually think the market's demonstrated lack of understanding about RAC may have a positive impact on the share price. The market doesn't put enough weight on our current preclinicals as we've seen, because they aren't able to contextualise them against Bisantrene's historical in-human results and RAC's contemporary strategy, but I think with this announcement it's quite possible they will see the "in human" aspect of the announcement and give the share price a boost as a result, even though this specific trial isn't the most critical of our in-human trials.